Nasdaq
$6.81▲ 0.29%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $868.2MShares out 1.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 9.10Overnight26.09.10 10:394Ownership#●●●
ALUMIS INC.
Insider Srinivas Akkaraju of Alumis Inc. reported changes in beneficial ownership of securities as of September 4, 2026. This filing is a standard Form 4 disclosure regarding equity transactions by an executive or major shareholder.…more
$6.81+0.29%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.1Pre-market26.09.01 21:308-KKey event
ALUMIS INC.
Alumis announced that its Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus (SLE) failed to meet primary and secondary endpoints in the overall patient population. However, the company observed robust clinical responses in the prespecified IFNGS-high subgroup, supporting plans to discuss Phase 3 development with regulators, while maintaining its 4Q 2026 timeline for the NDA submission for plaque psoriasis.…more
$6.81+0.29%vs prev closeView filingShare - 8.17Pre-market26.08.17 19:09SCHEDULE 13DOwnership
ALUMIS INC.
Foresite Capital funds and James B. Tananbaum have entered into an agreement to jointly file a Schedule 13D regarding their common stock holdings in Latigo Biotherapeutics, Inc. This agreement, dated August 17, 2026, formalizes the joint reporting of their equity positions in the company.…more
$6.81+0.29%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9Pre-market26.10.09 17:00#●●●#●●●#●●●
Alumis Reports Positive Phase 3 Data for Psoriasis Treatment
Alumis announced positive Phase 3 clinical results for its psoriasis treatment, demonstrating significant symptom relief and quality-of-life improvements. The company remains on track to submit a new drug application in the fourth quarter of 2026.…more
$6.81+0.29%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.4Pre-market26.09.04 21:00
●●●●●●●● ●●●●● ●●●●●●
Alumis announced its participation in several upcoming healthcare investor conferences throughout September. These events are intended for investor engagement and do not provide immediate material impact on the stock price.…more
$6.81+0.29%vs prev close - 9.1Regular26.09.01 23:56
●●●●●●●● ●●●●● ●●●●●●
Alumis stock fell significantly after its Phase 2b trial for a lupus treatment failed to meet primary and secondary endpoints. While the company noted efficacy in a specific patient subgroup, the overall trial failure has negatively impacted investor sentiment.…more
$6.81+0.29%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report